- Home
- GLO vs AMRN Comparison
GLO vs AMRN Comparison
Compare GLO & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLO
- AMRN
- Stock Information
- Founded
- GLO 2006
- AMRN 1989
- Country
- GLO United States
- AMRN Ireland
- Employees
- GLO N/A
- AMRN N/A
- Industry
- GLO Finance/Investors Services
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- GLO Finance
- AMRN Health Care
- Exchange
- GLO Nasdaq
- AMRN Nasdaq
- Market Cap
- GLO 221.1M
- AMRN 189.2M
- IPO Year
- GLO N/A
- AMRN 1993
- Fundamental
- Price
- GLO $4.91
- AMRN $0.44
- Analyst Decision
- GLO
- AMRN Buy
- Analyst Count
- GLO 0
- AMRN 1
- Target Price
- GLO N/A
- AMRN N/A
- AVG Volume (30 Days)
- GLO 170.5K
- AMRN 2.2M
- Earning Date
- GLO 01-01-0001
- AMRN 03-12-2025
- Dividend Yield
- GLO 11.38%
- AMRN N/A
- EPS Growth
- GLO N/A
- AMRN N/A
- EPS
- GLO N/A
- AMRN N/A
- Revenue
- GLO N/A
- AMRN $228,614,000.00
- Revenue This Year
- GLO N/A
- AMRN N/A
- Revenue Next Year
- GLO N/A
- AMRN $19.11
- P/E Ratio
- GLO N/A
- AMRN N/A
- Revenue Growth
- GLO N/A
- AMRN N/A
- 52 Week Low
- GLO $4.08
- AMRN $0.35
- 52 Week High
- GLO $5.18
- AMRN $1.11
- Technical
- Relative Strength Index (RSI)
- GLO 38.30
- AMRN 39.44
- Support Level
- GLO $4.86
- AMRN $0.44
- Resistance Level
- GLO $5.00
- AMRN $0.47
- Average True Range (ATR)
- GLO 0.06
- AMRN 0.04
- MACD
- GLO 0.01
- AMRN 0.00
- Stochastic Oscillator
- GLO 36.11
- AMRN 60.13
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.